Journal of breast imaging · 2025
Performance of Abbreviated Breast MRI in High-Risk Patients in a Tertiary Care Academic Medical Center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zaza Tamara, Chandora Kapil, Yalniz Ceren, Zamora Kathryn Watts, Zalasin Stefanie, Li Yufeng, Woodard Stefanie
Аннотация
INTRODUCTION: The development of abbreviated breast MRI (AB-MRI) protocols reduce scan times. This paper reports the performance of AB-MRI at a tertiary care public academic medical center in comparison with established literature.
METHODS: This HIPAA-compliant IRB-approved retrospective study reviewed 413 AB-MRI screenings in high-risk patients from June 2020 to March 2023. Data were collected from 3 databases (MagView, Cerner PowerChart, and Prism Primordial). Demographics and overall BI-RADS assessment were recorded. For all positive (BI-RADS 0, 3, 4, 5) examinations, manual review of each case was performed. Performance metrics (sensitivity, specificity, cancer detection rate [CDR], recall rate, positive predictive value [PPV] 3 and negative predictive value [NPV]) were calculated. PubMed and Google Scholar were used to review similar AB-MRI studies to compare performance metrics.
RESULTS: There were 413 AB-MRI examinations from 413 unique patients. The majority of cases were audit-negative BI-RADS 1 or 2 (83.8%, 346/413). There were 67 (16.2%, 67/413) audit-positive cases with 3.6% (15/413) BI-RADS 3, 10.9% (45/413) BI-RADS 4, 0.7% (3/413) BI-RADS 5, and 1.0% (4/413) BI-RADS 0. Performance metrics showed a sensitivity of 100.0% (95% CI, 63.1%-100.0%) and a specificity of 85.7% (95% CI, 81.9%-88.9%). The PPV3 was 14.3% (95% CI, 5.1%-23.5%), and the NPV was 100.0% (95% CI, 99.0%-100.0%). The CDR was 19.4 per 1000 screenings. The results are comparable to prior literature and benchmark data.
CONCLUSION: This study demonstrates high sensitivity (100.0%) and NPV (100.0%) of AB-MRI with comparable specificity (85.7%) and CDR (19.4/1000) to the literature, adding support to the use of AB-MRI. Further research is needed to optimize AB-MRI protocols.
METHODS: This HIPAA-compliant IRB-approved retrospective study reviewed 413 AB-MRI screenings in high-risk patients from June 2020 to March 2023. Data were collected from 3 databases (MagView, Cerner PowerChart, and Prism Primordial). Demographics and overall BI-RADS assessment were recorded. For all positive (BI-RADS 0, 3, 4, 5) examinations, manual review of each case was performed. Performance metrics (sensitivity, specificity, cancer detection rate [CDR], recall rate, positive predictive value [PPV] 3 and negative predictive value [NPV]) were calculated. PubMed and Google Scholar were used to review similar AB-MRI studies to compare performance metrics.
RESULTS: There were 413 AB-MRI examinations from 413 unique patients. The majority of cases were audit-negative BI-RADS 1 or 2 (83.8%, 346/413). There were 67 (16.2%, 67/413) audit-positive cases with 3.6% (15/413) BI-RADS 3, 10.9% (45/413) BI-RADS 4, 0.7% (3/413) BI-RADS 5, and 1.0% (4/413) BI-RADS 0. Performance metrics showed a sensitivity of 100.0% (95% CI, 63.1%-100.0%) and a specificity of 85.7% (95% CI, 81.9%-88.9%). The PPV3 was 14.3% (95% CI, 5.1%-23.5%), and the NPV was 100.0% (95% CI, 99.0%-100.0%). The CDR was 19.4 per 1000 screenings. The results are comparable to prior literature and benchmark data.
CONCLUSION: This study demonstrates high sensitivity (100.0%) and NPV (100.0%) of AB-MRI with comparable specificity (85.7%) and CDR (19.4/1000) to the literature, adding support to the use of AB-MRI. Further research is needed to optimize AB-MRI protocols.